Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move ...

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...